LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 153

Search options

  1. Article ; Online: Presence of tumor deposits is a strong indicator of poor outcome in patients with stage III colorectal cancers undergoing radical surgery.

    Lieto, Eva / Auricchio, Annamaria / Ronchi, Andrea / Del Sorbo, Giovanni / Panarese, Iacopo / Ferraraccio, Francesca / De Vita, Ferdinando / Galizia, Gennaro / Cardella, Francesca

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

    2024  Volume 28, Issue 1, Page(s) 47–56

    Abstract: Background: Tumor deposits (TDs) are emerging as an adverse prognostic factor in colorectal cancers (CRCs). However, TDs are somewhat neglected in the current staging system. It has been proposed either to add the TD count to the number of metastatic ... ...

    Abstract Background: Tumor deposits (TDs) are emerging as an adverse prognostic factor in colorectal cancers (CRCs). However, TDs are somewhat neglected in the current staging system. It has been proposed either to add the TD count to the number of metastatic lymph nodes or to consider TDs as distant metastases; however, the scientific basis for these proposals seems questionable. This study aimed to investigate a new staging system.
    Methods: A total of 243 consecutive patients with stage III CRC who were undergoing curative resection and adjuvant chemotherapy were included. Each substage of stage III TNM was split according to the absence or presence of TDs. Receiver operating characteristic (ROC) curves and bootstrap methods were used to compare the current vs the new competing staging system in terms of oncologic outcome prediction.
    Results: A high rate of TDs was recorded (124 cases [51%]). TDs were correlated with other adverse prognostic indicators, particularly vascular and perineural invasions, and showed a negative correlation with the number of removed lymph nodes, suggesting a possible multimodal origin. In addition, TDs were confirmed to have a negative impact on oncologic outcome, regardless of their counts. Compared with the current staging system, the new classification displayed higher values at survival ROC analysis, a significantly better stratification of patients, and effective identification of patients at high risk of recurrence.
    Conclusions: TDs negatively affect the prognosis in CRCs. A revision of the staging system could be useful to optimize treatments. The proposed new classification is easy to implement and more accurate than the current one. This study was registered online on the ClinicalTrials.gov website under the following identifier: NCT05923450.
    MeSH term(s) Humans ; Colorectal Neoplasms/pathology ; Extranodal Extension/pathology ; Neoplasm Staging ; Prognosis
    Language English
    Publishing date 2024-02-14
    Publishing country United States
    Document type Clinical Study ; Journal Article
    ZDB-ID 2012365-6
    ISSN 1873-4626 ; 1934-3213 ; 1091-255X
    ISSN (online) 1873-4626 ; 1934-3213
    ISSN 1091-255X
    DOI 10.1016/j.gassur.2023.11.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Assessment of the DNA Mismatch Repair System Is Crucial in Colorectal Cancers Necessitating Adjuvant Treatment: A Propensity Score-Matched and Win Ratio Analysis.

    Lieto, Eva / Cardella, Francesca / Wang, Duolao / Ronchi, Andrea / Del Sorbo, Giovanni / Panarese, Iacopo / Ferraraccio, Francesca / De Vita, Ferdinando / Galizia, Gennaro / Auricchio, Annamaria

    Cancers

    2023  Volume 16, Issue 1

    Abstract: A deficient DNA mismatch repair (MMR) system is identified in a non-negligible part of sporadic colorectal cancers (CRCs), and its prognostic value remains controversial. High tumor mutational burden, along with a poor response to conventional ... ...

    Abstract A deficient DNA mismatch repair (MMR) system is identified in a non-negligible part of sporadic colorectal cancers (CRCs), and its prognostic value remains controversial. High tumor mutational burden, along with a poor response to conventional chemotherapy and excellent results from immunotherapy, are the main features of this subset. The aim of this study was to evaluate the predictive value of DNA MMR system status for its best treatment. Four hundred and three CRC patients, operated on from 2014 to 2021 and not treated with immunotherapy, entered this study. Immunohistochemistry and polymerase chain reaction, as appropriate, were used to unequivocally group specimens into microsatellite stable (MSS) and instable (MSI) tumors. The win-ratio approach was utilized to compare composite outcomes. MSI tumors accounted for 12.9% of all series. The right tumor location represented the most important factor related to MSI. The status of the DNA MMR system did not appear to correlate with outcome in early-stage CRCs not requiring adjuvant treatment; in advanced stages undergoing conventional chemotherapy, MSI tumors showed significantly poorer overall and disease-free survival rates and the highest win ratio instead. The determination of DNA MMR status is crucial to recommending correct management. There is clear evidence that instable CRCs needing adjuvant therapy should undergo appropriate treatments.
    Language English
    Publishing date 2023-12-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16010134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab-paclitaxel therapy outcome in advanced gastric cancer: results of prospective study.

    D'Alessandro, Rosalba / Refolo, Maria Grazia / Schirizzi, Annalisa / De Leonardis, Giampiero / Donghia, Rossella / Guerra, Vito / Giannelli, Gianluigi / Lolli, Ivan Roberto / Laterza, Maria Maddalena / De Vita, Ferdinando / Messa, Caterina / Lotesoriere, Claudio

    Frontiers in oncology

    2023  Volume 13, Page(s) 1187014

    Abstract: This corrects the article DOI: 10.3389/fonc.2022.862116.]. ...

    Abstract [This corrects the article DOI: 10.3389/fonc.2022.862116.].
    Language English
    Publishing date 2023-04-14
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1187014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.

    Zannini, Giuseppa / Facchini, Gaetano / De Sio, Marco / De Vita, Ferdinando / Ronchi, Andrea / Orditura, Michele / Vietri, Maria Teresa / Ciardiello, Fortunato / Franco, Renato / Accardo, Marina / Zito Marino, Federica

    Pathology, research and practice

    2023  Volume 243, Page(s) 154336

    Abstract: BRCA1 and BRCA2 are onco-suppressor genes involved in the DNA repair mechanism. The presence of BRCA1/2 mutations confers a higher risk of developing several cancer types. To date, the FDA approved various PARP inhibitors to treat selected BRCA1/2 ... ...

    Abstract BRCA1 and BRCA2 are onco-suppressor genes involved in the DNA repair mechanism. The presence of BRCA1/2 mutations confers a higher risk of developing several cancer types. To date, the FDA approved various PARP inhibitors to treat selected BRCA1/2 mutated oncologic patients. At first, PARP inhibitors were approved for patients with ovarian and breast cancers, and subsequently for metastatic pancreatic adenocarcinoma and metastatic castration-resistant prostate cancer after the treatment with chemotherapy. The current guidelines for BRCA testing are very heterogeneous between the different types of tumors regarding the diagnostic algorithm and the type of sample to analyze, such as the blood for the germline mutations and the tumoral tissue for the somatic mutations. Few data have currently been described regarding the detection of BRCA1/2 somatic mutations in formalin-fixed paraffin-embedded (FFPE) samples. In this review, we propose an overview of the BRCA mutations in FFPE samples of several cancers, including breast, ovarian, fallopian tube, primary peritoneal, prostate, and pancreatic cancer. We summarize the types and the frequency of BRCA mutations, the guidelines approved for the test, the molecular assays used for the detection and the PARP inhibitors approved for each tumor type.
    MeSH term(s) Female ; Humans ; Male ; Adenocarcinoma ; BRCA1 Protein/genetics ; Formaldehyde ; Mutation/genetics ; Ovarian Neoplasms/pathology ; Pancreatic Neoplasms/genetics ; Paraffin Embedding ; Poly(ADP-ribose) Polymerase Inhibitors ; Genes, BRCA1 ; Genes, BRCA2 ; Pancreatic Neoplasms
    Chemical Substances BRCA1 Protein ; Formaldehyde (1HG84L3525) ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2023-01-23
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 391889-0
    ISSN 1618-0631 ; 0344-0338
    ISSN (online) 1618-0631
    ISSN 0344-0338
    DOI 10.1016/j.prp.2023.154336
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Retraction notice to "Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors" [Lung Cancer 71 (2011) 283-290].

    Morgillo, Floriana / D'Aiuto, Elena / Troiani, Teresa / Martinelli, Erika / Cascone, Tina / De Palma, Raffaele / Orditura, Michele / De Vita, Ferdinando / Ciardiello, Fortunato

    Lung cancer (Amsterdam, Netherlands)

    2023  Volume 181, Page(s) 107226

    Language English
    Publishing date 2023-05-09
    Publishing country Ireland
    Document type Journal Article ; Retraction of Publication
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2023.107226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Testicular/paratesticular mesothelial tumours: Uncommon histopathologic entities in a very complex anatomical site.

    Pagliuca, Francesca / Lucà, Stefano / De Sio, Marco / Arcaniolo, Davide / Facchini, Gaetano / De Martino, Marco / Esposito, Francesco / DE Vita, Ferdinando / Chieffi, Paolo / Franco, Renato

    Pathology, research and practice

    2023  Volume 253, Page(s) 155069

    Abstract: Mesothelial tumours of the testicular/paratesticular region are uncommon, poorly characterised and difficult-to-diagnose lesions. They encompass entirely benign proliferations (adenomatoid tumour) and malignant, very aggressive tumours (mesothelioma) ... ...

    Abstract Mesothelial tumours of the testicular/paratesticular region are uncommon, poorly characterised and difficult-to-diagnose lesions. They encompass entirely benign proliferations (adenomatoid tumour) and malignant, very aggressive tumours (mesothelioma) whose morphological features can be overlapping, highly variable and confounding. Moreover, testicular/paratesticular mesothelial tumours comprise relatively new entities with indolent behaviour (well-differentiated papillary mesothelial tumour) as well as tumours which cannot be correctly included in any of the aforementioned categories and whose classification is still controversial. The molecular profile of such tumours represents an open issue. In fact, despite the recent discoveries about the genomic landscape of mesothelial proliferations at other sites (pleura, peritoneum), testicular/paratesticular mesothelial tumours, and namely mesotheliomas, are too rare to be extensively studied on large case series and they could arguably hide relevant differences in their molecular background when compared to the more common pleural/peritoneal counterparts.The aim of this review is to provide a guide for the pathological assessment of testicular/paratesticular mesothelial tumours. Herein, we describe the most recent updates on this topic according to the latest (year 2022) World Health Organisation Classification of Urinary and Male Genital Tumours (5th edition) and current literature. The diagnostic criteria, the main differentials and the role of ancillary techniques in the diagnosis of mesothelial testicular/paratesticular tumours are discussed.
    MeSH term(s) Humans ; Male ; Testicular Neoplasms/pathology ; Genital Neoplasms, Male/pathology ; Epithelium/pathology ; Mesothelioma/pathology
    Language English
    Publishing date 2023-12-30
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 391889-0
    ISSN 1618-0631 ; 0344-0338
    ISSN (online) 1618-0631
    ISSN 0344-0338
    DOI 10.1016/j.prp.2023.155069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.

    Tehfe, Mustapha / Tabchi, Samer / Laterza, Maria Maddalena / De Vita, Ferdinando

    Future oncology (London, England)

    2018  Volume 14, Issue 3, Page(s) 223–228

    Abstract: Aim: Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive ...

    Abstract Aim: Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials & methods: We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel.
    Results: Most patients had a stable disease after ramucirumab-based therapy (50%, 5/10), median duration to disease control was 8 months.
    Conclusion: The prolonged duration of response that we observed indicates that an interaction between the EGF pathway and the angiogenesis pathway requires further clinical investigations.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Resistance, Neoplasm ; Esophageal Neoplasms/drug therapy ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/pathology ; Esophagogastric Junction/pathology ; Female ; Humans ; Male ; Middle Aged ; Molecular Targeted Therapy ; Receptor, ErbB-2/genetics ; Retreatment ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Trastuzumab/therapeutic use ; Treatment Outcome ; Ramucirumab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2018-01-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2274956-1
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2017-0434
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting.

    Pappalardo, Annalisa / Giunta, Emilio Francesco / Tirino, Giuseppe / Pompella, Luca / Federico, Piera / Daniele, Bruno / De Vita, Ferdinando / Petrillo, Angelica

    Frontiers in oncology

    2021  Volume 11, Page(s) 695627

    Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite progresses in surgical and pharmacological treatment in recent years. High potential for metastases is the main cause of therapeutic failure in localized ... ...

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite progresses in surgical and pharmacological treatment in recent years. High potential for metastases is the main cause of therapeutic failure in localized disease, highlighting the current limited knowledge of underlying pathological processes. However, nowadays research is focusing on the search for personalized approaches also in the adjuvant setting for PDAC, by implementing the use of biomarkers and investigating new therapeutic targets. In this context, the aim of this narrative review is to summarize the current treatment scenario and new potential therapeutic approaches in early stage PDAC, from both a preclinical and clinical point of view. Additionally, the review examines the role of target therapies in localized PDAC and the influence of neoadjuvant treatments on survival outcomes.
    Language English
    Publishing date 2021-08-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.695627
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN).

    Fornaro, Lorenzo / Spallanzani, Andrea / de Vita, Ferdinando / D'Ugo, Domenico / Falcone, Alfredo / Lorenzon, Laura / Tirino, Giuseppe / Cascinu, Stefano

    Cancers

    2021  Volume 13, Issue 6

    Abstract: Background: Management of gastric and gastroesophageal junction (GEJ) adenocarcinoma remains challenging, because of the heterogeneity in tumor biology within the upper gastrointestinal tract. Daily clinical practice is full of grey areas regarding the ... ...

    Abstract Background: Management of gastric and gastroesophageal junction (GEJ) adenocarcinoma remains challenging, because of the heterogeneity in tumor biology within the upper gastrointestinal tract. Daily clinical practice is full of grey areas regarding the complexity of diagnostic, staging, and therapeutic procedures. The aim of this paper is to provide a guide for clinicians facing challenging situations in routine practice, taking a multidisciplinary consensus approach based on available literature.
    Methods: The GAIN (GAstric cancer Italian Network) group was established with the aims of reviewing literature evidence, discussing key issues in prevention, diagnosis, and management of gastric and GEJ adenocarcinoma, and offering a summary of statements. A Delphi consensus method was used to obtain opinions from the expert panel of specialists.
    Results: Forty-nine clinical questions were identified in six areas of interest: role of multidisciplinary team; risk factors; diagnosis; management of early gastric cancer and multimodal approach to localized gastric cancer; treatment of elderly patients with locally advanced resectable disease; and treatment of locally advanced and metastatic cancer.
    Conclusions: The statements presented may guide clinicians in practical management of this disease.
    Language English
    Publishing date 2021-03-15
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13061304
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: An intramedullary "flame" recognized as being an intramedullary spinal cord metastasis from esophageal cancer.

    Grillo, Assunta / Capasso, Raffaella / Petrillo, Angelica / De Vita, Ferdinando / Conforti, Renata

    Journal of radiology case reports

    2019  Volume 13, Issue 7, Page(s) 14–20

    Abstract: Intramedullary spinal cord metastases are rarely encountered in patients suffering from extra - central nervous system primary cancer, with only 2 described cases reported in the literature deriving from esophageal cancer. Intramedullary spinal cord ... ...

    Abstract Intramedullary spinal cord metastases are rarely encountered in patients suffering from extra - central nervous system primary cancer, with only 2 described cases reported in the literature deriving from esophageal cancer. Intramedullary spinal cord metastases may occur at any level of the spinal cord but cervical location is the most frequent. We report the first case of intramedullary metastasis affecting the thoracic spinal cord from esophageal squamous cell carcinoma in a 35-year-old patient.
    MeSH term(s) Adult ; Esophageal Neoplasms/pathology ; Esophageal Squamous Cell Carcinoma/pathology ; Fatal Outcome ; Female ; Humans ; Neoplasms, Second Primary/diagnostic imaging ; Spinal Cord/diagnostic imaging ; Spinal Cord Neoplasms/diagnostic imaging ; Spinal Cord Neoplasms/secondary
    Language English
    Publishing date 2019-07-31
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2586384-8
    ISSN 1943-0922 ; 1943-0922
    ISSN (online) 1943-0922
    ISSN 1943-0922
    DOI 10.3941/jrcr.v13i7.3555
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top